Evidence map›Paper›PMID 8350398›Full record

ArticleJournal of virology1993

Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes.

T W Hermiston, R A Tripp, T Sparer, L R Gooding, W S Wold

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of virology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Replication-selective adenoviruses as oncolytic agents.The Journal of clinical investigation · 2000
    Review
  17. Review
  18. Review
  19. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains.Proceedings of the National Academy of Sciences of the United States of America · 1996
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

T W HermistonDepartment of Molecular Microbiology and Immunology, St. Louis University School of Medicine, Missouri 63104.
R A Tripp
T Sparer
L R Gooding
W S Wold
Washington University in St. Louis · US

Funding

ADENOVIRUS GENES TUMOR NECROSIS FACTOR INTERACTIONSF32CA008896 · NCI · SAINT LOUIS UNIVERSITY · PI HERMISTON, TERRY W. · 1990 to 1992
–
ADENOVIRUS TWO CODED EARLY GLYCOPROTEINR01CA024710 · NCI · SAINT LOUIS UNIVERSITY · PI WOLD, WILLIAM SM · 1985 to 1997
–
NCI NIH HHS F32 CA08896NCI NIH HHS R01 CA24710
6 · The paper itself

Abstract

Adenovirus E3-gp19K is a transmembrane glycoprotein, localized in the endoplasmic reticulum (ER), which forms a complex with major histocompatibility complex (MHC) class I antigens and retains them in the ER, thereby preventing cytolysis by cytotoxic T lymphocytes (CTL). The ER lumenal domain of gp19K, residues 1 to 107, is known to be sufficient for binding to class I antigens; the transmembrane and cytoplasmic ER retention domains are located at residues ca. 108 to 127 and 128 to 142, respectively. To identify more precisely which gp19K regions are involved in binding to class I antigens, we constructed 13 in-frame virus deletion mutants (4 to 12 amino acids deleted) in the ER lumenal domain of gp19K, and we analyzed the ability of the mutant proteins to form a complex with class I antigens, retain them in the ER, and prevent cytolysis by adenovirus-specific CTL. All mutant proteins except one (residues 102 to 107 deleted) were defective for these properties, indicating that the ability of gp19K to bind to class I antigens is highly sensitive to mutation. All mutant proteins were stable and were retained in the ER. Sequence comparisons among adenovirus serotypes reveal that the ER lumenal domain of gp19K consists of a variable region (residues 1 to 76) and a conserved region (residues 77 to 98). We show, using the mutant proteins, that the gp19K-specific monoclonal antibody Tw1.3 recognizes a noncontiguous epitope in the variable region and that disruption of the variable region by deletion destroys the epitope. The monoclonal antibody and class I antigen binding results, together with the serotype sequence comparisons, are consistent with the idea that the ER lumenal domain of gp19K has three subdomains that we have termed the ER lumenal variable domain (residues 1 to ca. 77 to 83), the ER lumenal conserved domain (residues ca. 84 to 98), and the ER lumenal spacer domain (residues 99 to 107). We suggest that the ER lumenal variable domain of gp19K has a specific tertiary structure that is important for binding to the polymorphic alpha 1 and alpha 2 domains of class I heavy (alpha) chains. We suggest that the ER lumenal conserved domain of gp19K may interact with some conserved protein, perhaps the highly conserved alpha 3 domain of class I heavy chains. Finally, the ER lumenal spacer domain may allow the ER lumenal variable and conserved domains to extend out from the ER membrane so that they can interact with class I heavy chains.

Indexed as

AdenoviridaeAdenovirus E3 ProteinsAdenoviruses, HumanAmino Acid SequenceBase SequenceCell LineEndoplasmic ReticulumFluorescent Antibody TechniqueGenes, ViralHistocompatibility Antigens Class IHumansMolecular Sequence DataMutagenesisOligodeoxyribonucleotidesPolymerase Chain ReactionProtein Sorting SignalsAdenovirus E3 ProteinsHistocompatibility Antigens Class IOligodeoxyribonucleotidesProtein Sorting Signals

Identifiers

PMID8350398
PMCPMC237927
OpenAlexW1565782295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.